WIPO Director Pleads With Countries To Advance Treaty For Visually Impaired 19/11/2012 by Catherine Saez, Intellectual Property Watch 4 Comments Visually impaired and print-disabled persons have high expectations for the results of this week’s negotiations on copyright exceptions and limitations at the World Intellectual Property Organization, WIPO Director General Francis Gurry told the opening of a committee meeting today.
Serageldin: IPR Adaptation Needed To Help Innovation Reach Small Farmers 19/11/2012 by Catherine Saez, Intellectual Property Watch Leave a Comment The director of the Library of Alexandria, Egypt, invited to speak about innovation and food security at the World Intellectual Property Organization last week, said science should reach small farmers in order face the challenge of global food security and increase agricultural yields. He also called for the IP regime to be tailored to serve that purpose.
Global Fund Names Mark Dybul Executive Director 15/11/2012 by Intellectual Property Watch 3 Comments The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria appointed Ambassador Mark Dybul, a former US Global AIDS Coordinator, as the new head of the organisation. Additionally, the Board decided to move forward on implementing a new funding model, replacing the rounds-based system.
EU Parliament, Scientists Press Governments To Boost Research Funding 15/11/2012 by Dugie Standeford for Intellectual Property Watch Leave a Comment As governments prepare to debate the European Union’s overall budget for 2014-2020, European Parliament members and top scientists today warned that any cuts to research and innovation funding will risk the loss of a generation of scientists just when Europe needs them most.
Recent Research Highlights Potential Of Open Access In Drug Discovery 14/11/2012 by Rachel Marusak Hermann, Intellectual Property Watch Leave a Comment The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announced the identification of three potential drug classes for the treatment of neglected tropical diseases through the availability of hundreds of compounds in the public domain.
Medicines Patent Pool Names New Director 14/11/2012 by Intellectual Property Watch Leave a Comment Greg Perry, a longtime leader in the European generics industry, has been named the new executive director of the Medicines Patent Pool, a cutting-edge Geneva-based group working to increase access to affordable, high-quality medicines for HIV/AIDS patients in low and middle income countries.
Analysis: Argentine Court Clarifies What Patent Holders Can – And Cannot – Prohibit 14/11/2012 by Maximiliano Marzetti for Intellectual Property Watch Leave a Comment In the recent decision on the case “Novartis AG versus Laboratorios LKM SA re cease of use of patent” the Third Chamber of the Federal Civil and Commercial Appellate Court of Argentina set an important precedent in relation to the interpretation of the ius prohibendi of patent holders. In other words, the demarcation of what they can and cannot prohibit.
Next Global Fund Director To Be Chosen From Four Candidates This Week 12/11/2012 by William New, Intellectual Property Watch 1 Comment The Global Fund against AIDS, Tuberculosis and Malaria, a health financing institution focused on the global South, is poised this week to select its next director – from the North. And while the selection process has been conducted in the utmost secrecy, confidential selection documents show that the list is down to four candidates, said to be from Canada, France, the United Kingdom, and the United States.
Study Shows Drug Patents Can Be Extended For Decades 09/11/2012 by Intellectual Property Watch 1 Comment The industry practice of extending patent protection on pharmaceuticals by obtaining additional patents on other features of the drug ingredients can lead to decades of delay in generic competition, a new study argues.
Technical Meeting Advances Ideas For WHO-Led R&D Financing Framework 09/11/2012 by Intellectual Property Watch 1 Comment An outside meeting of experts has prepared a report ahead of this month’s gathering of World Health Organization members hoping to agree on new models for financing research and development for diseases lacking adequate market mechanisms and public policies. These include neglected diseases that predominantly affect poor populations unable to pay high prices needed to defray R&D costs under the existing commercial model.